Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials
Year: 2014
Type: article
Study design: Clinical Trial
Source: The Lancet Respiratory Medicine
Authors: Marc Decramer, Antonio Anzueto, Edward Kerwin, Thomas Kaelin, Nathalie Richard, Glenn Crater, Maggie Tabberer, Stephanie Harris, Alison Church
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: umeclidinium, vilanterol, tiotropium, chronic obstructive pulmonary disease, long-acting bronchodilators, combination therapy, FEV1, lung function, adverse events, dry powder inhaler, HandiHaler, Ellipta, COPD exacerbations, COPD hospitalization, COPD mortality, COPD-related emergency department visits
Open Access status: closed
Funder: GlaxoSmithKline
OpenAlex ID: W2026585673
